Summary
The United States District Court for the Southern District of California grants defendants’ motion to dismiss a consolidated securities-fraud complaint against Dexcom, Inc. and several executives. The court concludes that the complaint is an impermissible puzzle pleading because it does not clearly identify which portions of challenged statements are alleged to be false or misleading or connect those statements to the reasons for the alleged falsity. Dismissal is granted with leave to amend, with the plaintiff given fourteen days to file a first amended consolidated complaint.
Topics
Practice areas
Questions Presented
- Whether the Consolidated Complaint adequately identified the specific statements alleged to be false or misleading and matched each statement with the reasons it was misleading as required by Rule 8 and the PSLRA.
- Whether dismissal should be granted with leave to amend.
Holdings
- The Consolidated Complaint failed to comply with Rule 8 and the PSLRA because it did not clearly identify which portions of the challenged statements were alleged to be false or misleading or explain why each challenged statement was misleading.
- The dismissal was entered with leave to amend, and Lead Plaintiff was permitted fourteen days to file a First Amended Consolidated Complaint.
Key quotations
“These requirements present no small hurdle for the securities fraud plaintiff.” (at 4)
“In short, “plaintiffs have left it up to defendants and the court to try to figure out exactly what the misleading statements are, and to match the statements up with the reasons they are false or misleading.”” (at 10)
“For the above reasons, the Court GRANTS Defendants’ motion to dismiss WITH LEAVE TO AMEND.” (at 11)
Factual background
Dexcom develops and sells continuous glucose monitoring devices and promoted its ability to gain market share in the Type 2 basal-insulin market after expanded Medicare coverage. The complaint alleged that Dexcom and three executives made fourteen false or misleading statements about the company's sales force, market position, prescribing trends, reimbursement, and market share between April 2023 and June 2024. After Dexcom reduced its full-year revenue guidance on July 25, 2024, its stock price fell by more than 40%.
Procedural history
The court consolidated three securities class actions, appointed National Elevator Industry Pension Fund as Lead Plaintiff, and appointed Robbins Geller as Lead Counsel. Lead Plaintiff filed a Consolidated Complaint on January 27, 2025. Defendants moved to dismiss, and after briefing the court granted the motion with leave to amend within fourteen days.